about
18 F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkersRandomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain studyStructural imaging measures of brain aging.Advances in MRI biomarkers for the diagnosis of Alzheimer's disease.Current status and future role of brain PET/MRI in clinical and research settings.Structural Neuroimaging of the Medial Temporal Lobe in Alzheimer's Disease Clinical Trials.PET Neurochemical Imaging Modes.White matter damage disorganizes brain functional networks in amnestic mild cognitive impairmentAβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical settingImaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?Molecular imaging of Alzheimer disease pathologyVolume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study.The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.Utility of oblique coronal images in elderly and cognitively impaired patientsInfluence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain KineticsAccelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's diseaseCross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.Validation of 18F-FDG-PET Single-Subject Optimized SPM Procedure with Different PET Scanners.Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.Non-Alzheimer's disease-related memory impairment and dementia.Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer DiseaseUsefulness of 3-dimensional stereotactic surface projection FDG PET images for the diagnosis of dementia.Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?Memory performance-related dynamic brain connectivity indicates pathological burden and genetic risk for Alzheimer's disease.Lipidomics of Alzheimer's disease.Advances in imaging-genetic relationships for Alzheimer's disease: clinical implications.FDG-PET Contributions to the Pathophysiology of Memory Impairment.A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.Framingham Risk Score and the Risk of Progression from Mild Cognitive Impairment to Dementia.Non human primate models for Alzheimer's disease-related research and drug discovery.Simultaneous PET-MRI Studies of the Concordance of Atrophy and Hypometabolism in Syndromic Variants of Alzheimer's Disease and Frontotemporal Dementia: An Extended Case Series.Combining SPECT and Quantitative EEG Analysis for the Automated Differential Diagnosis of Disorders with Amnestic Symptoms.The emerging role of PET imaging in dementia.The first genetic biomarker for dementia with Lewy bodies.Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.Regional glucose hypometabolic spread within the primary motor cortex is associated with amyotrophic lateral sclerosis disease progression: A fluoro-deoxyglucose positron emission tomography study.FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.Visual Rating of Posterior Atrophy as a Marker of Progression to Dementia in Mild Cognitive Impairment Patients.
P2860
Q24186399-D7898B14-A02C-41AF-A10D-A9D2E4988D50Q26825442-8BA8CD68-342F-4407-A507-D00AA17C70F0Q30366283-2BC2D1DE-5B02-47A4-97F3-E72A12A2C864Q30844186-D41B15BB-76D2-4E02-90E2-992EBF2F3E82Q30870223-3A9337F4-BC4B-4D0F-8C07-5A0D9806B725Q30883711-B080CBAA-CCEF-45EA-BCCC-CA7D5AFA1137Q30996733-64CFD2E7-8684-4E1D-B62A-F5E8B2B58D94Q31033080-0496CD4F-F489-48B2-AA1E-E60DBB1B5830Q33782788-593F1A4C-B911-4742-8F2E-6CBCB485AAE8Q34426744-E221CE2E-BE16-49B5-9731-D0A02C6FAC16Q34477727-E15F0AF8-120D-454D-B14F-6A8370164ACFQ34629872-E2275A5B-DA5E-463E-978B-CFFC4895859BQ34651135-AB09A4B1-D2C9-450D-AC62-F01C9C2F9313Q34988405-C3996EFF-F12C-4CF1-9B26-AB7FAD02EFBDQ34989647-748E46E3-06DE-4887-8BE8-5433D5C9A783Q35291308-D2F08E87-04AE-4C11-82E0-4D1559293683Q35529180-89C19B2A-1FC2-47D3-A880-80710016D9AAQ35686223-E09EB6FC-627D-42AE-8EE6-413D92D62736Q35765058-4FD7923F-8E8C-4053-A5C5-744831E1577AQ36243629-316CD4BD-9523-40D4-A17A-4A7E01475978Q36929890-20D02FA3-D587-4046-9F62-E6C356B08DD8Q37503811-68B20BC3-2555-495F-96AA-EE974E1E59B9Q37559815-339F623B-7A20-4595-882B-1CD03CE7665CQ37606199-8D23D463-D257-44BA-A333-66E653E7E9A5Q37690944-B7A07E7B-EC12-4B9C-A3BC-C1C975E975A0Q37731606-F32765F8-8F7A-4586-8652-834A3D4BDB7EQ38191024-6EF08A0E-F602-4415-A81D-188E60046EB1Q38196862-D0FEF34B-8C58-4908-82E1-A1BE718409B6Q38576278-C2AA7174-551D-41AD-B30E-D64193582295Q38697140-519D7D1D-0E3B-4FED-BDB1-80FA9BD1117DQ38742995-1BCCA117-81B8-4934-B648-3D73CF09C5ADQ38783343-BC8AEDAF-69A9-44FA-BDF9-9718AFA337BCQ38960508-DC8FEF6F-8B7F-4C81-9B83-63A45CF94576Q41299901-5800F904-6472-499E-A98E-7902112DA3A5Q42701971-DCE1C6D8-5DE3-4E9D-8FBC-7BE1287C7747Q43528737-FF382838-2390-4EFD-8301-D14BC4868188Q46133238-FEA1FFB4-B258-4FF2-8A75-0D24564C3964Q47142121-450A69AD-747B-429B-A095-054B53B7D73FQ47553874-429DDA9C-A53D-405C-B18A-962FEF70935BQ47684888-78484ADE-047F-45E9-8060-F930371D325C
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Imaging markers for Alzheimer disease: which vs how
@ast
Imaging markers for Alzheimer disease: which vs how
@en
Imaging markers for Alzheimer disease: which vs how
@nl
type
label
Imaging markers for Alzheimer disease: which vs how
@ast
Imaging markers for Alzheimer disease: which vs how
@en
Imaging markers for Alzheimer disease: which vs how
@nl
prefLabel
Imaging markers for Alzheimer disease: which vs how
@ast
Imaging markers for Alzheimer disease: which vs how
@en
Imaging markers for Alzheimer disease: which vs how
@nl
P2093
P2860
P50
P1433
P1476
Imaging markers for Alzheimer disease: which vs how
@en
P2093
Charles Decarli
Christopher C Rowe
Clifford R Jack
Eric M Reiman
Frederik Barkhof
Gael Chételat
ISTAART's NeuroImaging Professional Interest Area
Karl Herholz
Keith A Johnson
Maria C Carrillo
P2860
P304
P356
10.1212/WNL.0B013E31829D86E8
P407
P50
P577
2013-07-01T00:00:00Z